Analyst consensus rating
Bone Biologics Analyst Rating: Strong Buy
BBLG is rated Strong Buy by 1 analysts with a $12.20 target. As of 2026-08-23.
Direct answer
Bone Biologics's consensus rating is Strong Buy.
1 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $12.20.
Forecast evidence checked August 23, 2026.
Get free Bone Biologics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $0.63
- Average price target
- $12.20
- High price target
- $12.20
- Low price target
- $12.20
- Low target gap
- +1,848.3%
- Target upside
- +1,848.3%
- High target gap
- +1,848.3%
- Target range width
- 0%
- Consensus rating
- Strong Buy
- Analysts
- 1
- Evidence date
- August 23, 2026
- Valid through
- August 30, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Bone Biologics?
Bone Biologics has a verified Strong Buy consensus. The same dataset has an average price target of $12.20.
How far are Bone Biologics's low and high targets from the recorded price?
The low target implies +1,848.3%, while the high target implies +1,848.3%.
How many analysts are included in Bone Biologics's consensus?
The verified consensus includes 1 analysts.
How is Bone Biologics's target upside or downside calculated?
The average target of $12.20 is divided by the recorded price of $0.63, then one is subtracted to produce +1,848.3%. This does not guarantee a future return.
When was Bone Biologics's analyst forecast verified?
The data was verified on 2026-08-23. The dataset is valid through 2026-08-30.